Clinical Trial Update: Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 study comparing a quadrivalent meningococcal conjugate vaccine given as a single dose to a reference vaccine in participants aged 2 to 55 years. Results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenQuadfi (Meningococcal quadrivalent conjugate vaccine)
• Meningococcal reference vaccine

Snippet

Sponsor: Sanofi | Conditions: Meningococcal Immunisation (Healthy Volunteers) | Phase 3 | Status: COMPLETED | Results posted: 2021-10-06